The Effect of Age on von Willebrand Factor and Bleeding Symptoms in von Willebrand Disease

Craig D. Seaman1,2 Margaret V. Ragni1,2

1 Division of Hematology/Oncology, Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
2 Hemophilia Center of Western Pennsylvania, Pittsburgh, Pennsylvania, United States

Address for correspondence Craig D. Seaman, MD, Division of Hematology/Oncology, University of Pittsburgh, 3636 Boulevard of the Allies, Pittsburgh, PA 15213-4306, United States (e-mail: seamanc@upmc.edu).

Introduction

von Willebrand disease (VWD) is a quantitative or qualitative defect in von Willebrand factor (VWF) resulting in mucocutaneous bleeding symptoms and hemorrhage following hemostatic challenges, such as trauma or surgery. VWD-specific therapy, DDAVP (1-desamino-8-D-arginine vasopressin) and VWF concentrates, is necessary periprocedurally to ensure adequate hemostasis. The aging VWD patient may complicate this matter. The plasma concentration of many coagulation proteins, including VWF, increases with age. While it has been established that VWF levels increase with age in a healthy population, emerging research demonstrates this occurs in certain subtypes of VWD, too. Thus, the management of periprocedural VWD-specific therapy in the aging VWD patient is problematic when VWF levels increase over time to normal, and hematologists are left with uncertainty regarding whether or not periprocedural VWD-specific therapy is still necessary. In this article, we will review the current state of the literature regarding the effect of age on VWF levels in the healthy population and VWD while exploring possible etiologies for this phenomenon. Further, we will detail how this affects bleeding symptoms and highlight what research remains to be done to optimize care in this patient population.

Abstract

von Willebrand disease (VWD) is a quantitative or qualitative defect in von Willebrand factor (VWF) resulting in mucocutaneous bleeding symptoms and hemorrhage following hemostatic challenges, such as trauma or surgery. VWD-specific therapy, DDAVP (1-desamino-8-D-arginine vasopressin) and VWF concentrates, is necessary periprocedurally to ensure adequate hemostasis. The aging VWD patient may complicate this matter. The plasma concentration of many coagulation proteins, including VWF, increases with age. While it has been established that VWF levels increase with age in a healthy population, emerging research demonstrates this occurs in certain subtypes of VWD, too. Thus, the management of periprocedural VWD-specific therapy in the aging VWD patient is problematic when VWF levels increase over time to normal, and hematologists are left with uncertainty regarding whether or not periprocedural VWD-specific therapy is still necessary. In this article, we will review the current state of the literature regarding the effect of age on VWF levels in the healthy population and VWD while exploring possible etiologies for this phenomenon. Further, we will detail how this affects bleeding symptoms and highlight what research remains to be done to optimize care in this patient population.

Keywords

- von Willebrand disease
- von Willebrand factor
- age
- bleeding score

The management of periprocedural VWD-specific therapy is sometimes problematic in older patients. The plasma concentration of many coagulation proteins, including VWF, increases with age. While it has been established that VWF levels increase with age in a healthy population, emerging research demonstrates this occurs in certain subtypes of VWD, too. When VWF levels increase over time to normal (i.e., VWF: antigen [Ag] greater than or equal to 0.50 IU/mL), hematologists are faced with the dilemma whether or not VWF-specific therapy is indicated at the time of surgery. If VWD patients with normalized VWF levels are no longer at an increased risk of bleeding then periprocedural VWD-specific therapy may lead to thrombotic complications, especially given the increased risk of cardiovascular disease in older patients; thus, should be omitted. In this article, we will review the current
state of the literature regarding this topic to identify what is known and what research remains to be done to optimize care in this patient population.

Clinical Vignette
A 67-year-old female presents to clinic for preoperative hematologic clearance. She has a history of DAAP-responsive type 1 VWD, and she is scheduled to undergo a laparoscopic sigmoid colectomy for recurrent diverticulitis. She has not been seen in the clinic for more than 20 years. Her lowest recorded VWF:Ag level and VWF:ristocetin cofactor (RCo) activity were 0.41 and 0.38 IU/mL, respectively, more than 30 years ago. Her lifelong bleeding score determined with the condensed molecular and clinical markers for the diagnosis and management of type I (MCMDCM-1) BAT is 7 based on a history of easy bruising, epistaxis, menorrhagia requiring estrogen containing hormonal therapy, and excessive bleeding following wisdom teeth extraction. She denies any recent bleeding symptoms in the past several years; however, she is postmenopausal and has not required any invasive procedures during that time. VWF levels are repeated, and the VWF:Ag level is 0.95 IU/mL, and the VWF:RCo activity is 0.90 IU/mL. Factor VIII (FVIII) activity is 1.61 IU/mL. She is not receiving any exogenous estrogen therapy. Other pertinent medical history includes hypertension, type II diabetes mellitus, obesity, and remote tobacco abuse. Is VWD-specific therapy necessary perioperatively, and if so, what are the specific dosing recommendations?

Effect of Age on von Willebrand Factor in the General Population
The plasma concentration of many coagulation proteins, including fibrinogen, FVII, FVIII, FIX, and FXII, increases with age. Correspondingly, markers of coagulation activation, prothrombin fragment 1 + 2, thrombin–antithrombin III complex, and D-dimer, are elevated. Similarly, VWF levels increase with age. VWF is an acute phase reactant: 35% of the variability in VWF levels is explained by environmental (cigarette smoke), physiological (hormonal, exercise, and age), and pathologic (inflammation, atherosclerosis, and liver disease) factors, the incidence of which are increased in older adults. An Italian prospective study compared 74 centenarians and 110 controls (55 less than 45 years of age), excluding chronic disorders (malignancy, diabetes, cardiovascular, kidney disease, etc.) and reported VWF:Ag levels were significantly higher among centenarians. VWF:Ag levels were 0.77, 0.99, and 2.45 among O blood group and 1.15, 1.52, and 2.85 among non-O blood group younger controls (less than 45 years of age), older controls (45 years of age or older), and centenarians, respectively. Interestingly, using a laboratory database-established cut-off value of 17%, the proportion of individuals with a reduction in high molecular weight multimers (HMWM) was 0% in younger controls, 25% in older controls, and 51% in centenarians. HMWMs are the most hemostatically active multimers. A decrease in the proportion of HMWMs present may counteract any increase in coagulation activity seen with rising VWF levels. A cross-sectional study of 123 women showed that VWF:Ag levels and VWF:RCo activity increased by an average of 0.17 and 0.15 IU/mL, respectively, per decade of life. This is counterintuitive to the expectation that the decline in estrogen in postmenopausal females is paralleled by a reduction in VWF levels. Recently, a cross-sectional study of 207 patients showed increasing VWF levels with age is greatly influenced by ABO blood type. Elderly individuals (age 55–87) with blood type O were observed to have a 1.25-fold increase in mean VWF:Ag levels, 1.68 ± 0.62 versus 0.98 ± 0.32 IU/mL, p < 0.001, compared with young individuals (age 1–17). Whereas, elderly individuals with blood type non-O demonstrated a 1.71-fold increase in mean VWF:Ag levels, 0.85 ± 0.25 versus 1.11 ± 0.38 IU/mL, p = 0.002, compared with young individuals. This suggests ABO, and possibly other non-VWF loci, contribute to age-related changes in VWF levels. Finally, when interpreting the results of studies investigating changes in VWF levels, it is important to keep in mind that VWF assays may not be completely reliable and have demonstrated an interlaboratory coefficient of variation as high as 30.

Effect of Age on von Willebrand Factor in von Willebrand Disease
While it has been established that VWF levels increase with age in a healthy population, emerging research demonstrates this occurs in VWD, too, and has been described in several observational studies (Table 1). A Canadian retrospective cohort study of 31 patients with type 1 VWD (historical VWF:Ag level and/or VWF:RCo activity less than 0.50 IU/mL) reported VWF:Ag levels and VWF:RCo activity increased by 0.30 IU/mL (95% confidence interval [CI], 0.21–0.39) and 0.20 IU/mL (95% CI, 0.13–0.27), respectively, per decade. The average duration of follow-up was 11 years, and during this time, the mean VWF:Ag level increased from 0.44 to 0.71 IU/mL, p < 0.001, and the mean VWF:RCo activity increased from 0.34 to 0.56 IU/mL, p < 0.001. In all, 58% of the patients had VWF:Ag levels and VWF:RCo activity that increased into the normal range. A similar retrospective cohort study looked at the relationship between age and VWF levels in 126 patients with a diagnosis of type 1 VWD (historical VWF:Ag level and/or VWF RCo activity less than 0.30 IU/mL or “low VWF” (historical VWF:Ag level and/or VWF:RCo activity 0.30–0.49 IU/mL). VWF:Ag levels and VWF:RCo activity increased 0.024 and 0.014 IU/mL, p < 0.001 each, respectively, per year. The average duration of follow-up was 10.5 years. Normalization of VWF:Ag levels and VWF:RCo activity occurred in 27.8% of patients. A third retrospective cohort study of 195 patients with type 1 VWD demonstrated a 0.14 ± 0.033 and 0.096 ± 0.02 IU/mL, p < 0.05 each, increase in mean VWF:Ag levels and VWF:RCo activity, respectively, between the first and last measurements during a 6.6-year median duration of follow-up. In a subgroup analysis of 143 patients with mild disease (VWF:Ag level and VWF:RCo activity 0.30–0.49 IU/mL) and 52 patients with moderate to severe disease (VWF:Ag level...
and VWF:RCo activity less than 0.30 IU/mL), an increase in VWF levels was restricted to those with mild disease. Among patients with mild disease, 94% experienced normalization of VWF:Ag levels and VWF:RCo activity at last follow-up compared with only 6% of patients with moderate to severe disease.

In contrast to the previously described retrospective studies, the Willebrand in the Netherlands (WiN) study was a cross-sectional study of patients with moderate to severe VWD (historical VWF:Ag level and/or VWF:RCo activity less than 0.30 IU/mL). Sanders et al. reported VWF:Ag level and VWF:RCo activity per decade age increases of 0.035 IU/mL (95% CI, 0.23–0.49) in patients without comorbidities to 0.44 IU/mL (95% CI, 0.29–0.62) in patients with one comorbidity to 0.67 IU/mL (95% CI, 0.39–0.90) in patients with two comorbidities.

### Table 1: Effect of age on von Willebrand factor in von Willebrand disease

<table>
<thead>
<tr>
<th>Study type</th>
<th>Author</th>
<th>Patient population</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Retrospective</td>
<td>Rydz et al</td>
<td>31 patients with type 1 VWD (historical VWF:Ag level and/or VWF:RCo activity less</td>
<td>VWF:Ag levels increased 0.30 IU/mL (95% CI, 0.21–0.39) per decade</td>
</tr>
<tr>
<td>cohort study</td>
<td>Canada</td>
<td>than 0.50 IU/mL)</td>
<td>Mean VWF:Ag level increased from 0.44 to 0.71 IU/mL, p &lt; 0.001, over an average duration</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Mean age at last observation 46 years (range 30–74 y)</td>
<td>of follow-up of 11 years</td>
</tr>
<tr>
<td></td>
<td></td>
<td>VWF:Ag levels increased into the normal range in 58% of patients</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Abou-Ismail et al</td>
<td>126 patients with type 1 VWD (historical VWF:Ag level and/or VWF:RCo activity less</td>
<td>VWF:Ag levels increased 0.024 IU/mL, p &lt; 0.001, per year</td>
</tr>
<tr>
<td></td>
<td>United States</td>
<td>than 0.30 IU/mL)</td>
<td>VWF:Ag levels increased in 27.8% of patients during an average duration of follow-up of 10.5</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Mean age at last observation 43.5 ± 21.5 years</td>
<td>years</td>
</tr>
<tr>
<td>Cross-sectional</td>
<td>Borghi et al</td>
<td>143 patients with mild type 1 VWD disease (VWF:Ag level and VWF:RCo activity less</td>
<td>VWF:Ag levels increased 0.14 ± 0.033 IU/mL, p &lt; 0.05, between the first and last</td>
</tr>
<tr>
<td>study</td>
<td>Italy</td>
<td>than 0.30 IU/mL)</td>
<td>measurements during a 6.6-year median duration of follow-up</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Mean age at first observation 28.7 y (range 0.4–74.5 y)</td>
<td>VWF:Ag levels did not increase in patients with moderate to severe type 1 VWD</td>
</tr>
<tr>
<td></td>
<td></td>
<td>VWF:Ag levels increased in 94% of patients with mild type 1 VWD compared with</td>
<td>VWF:Ag levels normalized in 94% of patients with mild type 1 VWD compared with 6% of</td>
</tr>
<tr>
<td></td>
<td></td>
<td>6% of patients with moderate to severe type 1 VWD</td>
<td>patients with moderate to severe type 1 VWD</td>
</tr>
<tr>
<td></td>
<td>Sanders et al</td>
<td>664 patients with moderate to severe VWD (historical VWF:Ag level and/or VWF:RCo</td>
<td>VWF:Ag levels were higher among 71 VWD patients 65 years of age and older compared with</td>
</tr>
<tr>
<td></td>
<td>Netherlands</td>
<td>activity less than 0.30 IU/mL)</td>
<td>593 VWD patients less than 65 years of age, 0.38 and 0.30 IU/mL, p = 0.033</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Mean age 71 years (range 65–85) in patients 65 years of age and older and</td>
<td>VWF:Ag levels increased 0.035 IU/mL (95% CI, −0.6 to 7.6) per decade among 40 patients,</td>
</tr>
<tr>
<td></td>
<td></td>
<td>43 years (range 16–64) in patients less than 65 years of age</td>
<td>age 65 or older, with type 1 VWD</td>
</tr>
<tr>
<td></td>
<td></td>
<td>VWF:Ag levels did not increase among 26 patients, age 65 or older, with type 1 VWD</td>
<td>VWF:Ag levels did not increase among 26 patients, age 65 or older, with type 1 VWD</td>
</tr>
<tr>
<td></td>
<td></td>
<td>VWF:Ag levels increased into the normal range in 58% of patients</td>
<td>VWF:Ag levels normalized in 94% of patients with mild type 1 VWD compared with 6% of</td>
</tr>
<tr>
<td></td>
<td></td>
<td>VWF:Ag levels increased in 27.8% of patients during an average duration of</td>
<td>patients with moderate to severe type 1 VWD</td>
</tr>
<tr>
<td></td>
<td></td>
<td>follow-up of 10.5 years</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Flood et al</td>
<td>310 patients with a historical diagnosis of type 1 VWD</td>
<td>172 of 310 (36%) patients with a historical diagnosis of type 1 VWD had normal VWF:Ag</td>
</tr>
<tr>
<td></td>
<td>United States</td>
<td>(median VWF:Ag level was 0.76 IU/mL)</td>
<td>levels when repeated at enrollment</td>
</tr>
<tr>
<td></td>
<td></td>
<td>VWF:Ag levels were higher among 71 VWD patients 65 years of age and older</td>
<td>(median VWF:Ag level was 0.76 IU/mL)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>compared with 593 VWD patients less than 65 years of age, 0.38 and 0.30 IU/mL,</td>
<td>VWF:Ag levels were higher among 71 VWD patients 65 years of age and older compared with</td>
</tr>
<tr>
<td></td>
<td></td>
<td>p = 0.033</td>
<td>593 VWD patients less than 65 years of age, 0.38 and 0.30 IU/mL, p = 0.033</td>
</tr>
<tr>
<td></td>
<td></td>
<td>VWF:Ag levels increased 0.035 IU/mL (95% CI, −0.6 to 7.6) per decade among 40</td>
<td>VWF:Ag levels increased 0.035 IU/mL (95% CI, −0.6 to 7.6) per decade among 40 patients,</td>
</tr>
<tr>
<td></td>
<td></td>
<td>patients, age 65 or older, with type 1 VWD</td>
<td>age 65 or older, with type 1 VWD</td>
</tr>
<tr>
<td></td>
<td></td>
<td>VWF:Ag levels did not increase among 26 patients, age 65 or older, with type 1 VWD</td>
<td>VWF:Ag levels did not increase among 26 patients, age 65 or older, with type 1 VWD</td>
</tr>
<tr>
<td></td>
<td></td>
<td>VWF:Ag levels increased into the normal range in 58% of patients</td>
<td>VWF:Ag levels increased into the normal range in 58% of patients</td>
</tr>
<tr>
<td></td>
<td></td>
<td>VWF:Ag levels increased in 27.8% of patients during an average duration of</td>
<td>VWF:Ag levels increased in 27.8% of patients during an average duration of follow-up of 10.5</td>
</tr>
<tr>
<td></td>
<td></td>
<td>follow-up of 10.5 years</td>
<td>years</td>
</tr>
<tr>
<td></td>
<td>Atiq et al</td>
<td>333 patients with type 1 VWD. Mean age 47 ± 15 years</td>
<td>VWF:Ag levels increased 0.03 IU/mL (95% CI, 0.01–0.04) per decade</td>
</tr>
<tr>
<td></td>
<td>Netherlands</td>
<td>VWF:Ag levels increased from 0.36 IU/mL (95% CI, 0.23–0.49) in patients without</td>
<td>VWF:Ag levels increased from 0.36 IU/mL (95% CI, 0.23–0.49) in patients without</td>
</tr>
<tr>
<td></td>
<td></td>
<td>comorbidities to 0.44 IU/mL (95% CI, 0.29–0.62) in patients with one comorbidity</td>
<td>comorbidities to 0.44 IU/mL (95% CI, 0.29–0.62) in patients with one comorbidity to 0.67 IU/mL</td>
</tr>
<tr>
<td></td>
<td></td>
<td>to 0.67 IU/mL (95% CI, 0.39–0.90) in patients with two comorbidities</td>
<td>(95% CI, 0.39–0.90) in patients with two comorbidities</td>
</tr>
</tbody>
</table>

### Footnotes:
- **Abbreviations:** CI, confidence interval; VWD, von Willebrand disease; VWF:Ag, von Willebrand factor:antigen; VWF:RCo, von Willebrand factor:ristocetin cofactor.
p = 0.033. A similar large multicenter study in the United States, the Zimmerman Program, enrolled patients with an institutional diagnosis of VWD. VWF levels were repeated at the time of enrollment, and 172 of 310 (36%) patients with a historical diagnosis of type 1 VWD had normal VWF levels. The median VWF:Ag level was 0.76 IU/mL, and the median VWF:RCo activity was 0.72 IU/mL.

The above findings indicate that VWF levels increase with age, and this increase may be restricted to patients with “low VWF” and type 1 VWD; however, the reasons for both are unclear. One reason for increasing VWF levels with age is the presence of comorbid illnesses. As mentioned previously, VWF is an acute phase reactant, and 35% of the variability of VWF levels is related to external factors, such as inflammation and other related conditions. Atiq et al explored this matter in their WiN study. Among 333 patients with type 1 VWD, hypertension, diabetes mellitus, cancer, and thyroid dysfunction were found to be associated with increased VWF levels. Further, as the number of comorbidities increased, so did VWF levels: VWF:Ag levels increased from 0.36 IU/mL (95% CI, 0.23–0.49) in patients without comorbidities to 0.44 IU/mL (95% CI, 0.29–0.62) in patients with one comorbidity to 0.67 IU/mL (95% CI, 0.39–0.90) in patients with two comorbidities. In the study, VWF:Ag levels and VWF:RCo activity increased 0.03 IU/mL (95% CI, 0.01–0.04) and 0.04 IU/mL (95% CI, 0.02–0.06), respectively, per decade. Following adjustment for comorbidities, the age-related increase in VWF levels was no longer observed. Future studies exploring the effect of inflammatory biomarkers, such as C-reactive protein, on VWF levels in the context of comorbidities is needed.

The variability in VWF levels with age may be limited to those with type 1 VWD, based on the presence or absence of a VWF mutation. Pathogenic VWF gene mutations have been identified in most cases of types 2 and 3 VWD, and several large population studies have identified VWF mutations in approximately 65% of type 1 VWD cases, which occur with greater frequency in more severe disease. It is proposed that the presence of VWF mutations, and associated defects in VWF synthesis and processing, prevent age-related increases in VWF levels in severe type 1 and types 2 and 3 VWD. Alternatively, it is surmised that age-related increases in VWF levels are most commonly experienced in individuals without VWF mutations, which typically occurs in patients with mild type 1 VWD, or “low VWF” (VWF:Ag level 0.30–0.50 IU/mL), where the decrease in VWF levels is probably explained by the effect of non-VWF genetic loci on VWF secretion, clearance, and glycosylation. Heritability accounts for approximately 65% of the variability in VWF levels with 5% of heritability explained by the VWF gene and non-VWF genetic loci responsible for the remainder, including the ABO locus, which accounts for 25% of variability in VWF levels, CLEC4M, STAB2, and STXBP5, among others. Hence, VWF mutations correlate with the severity of disease, and if the presence of such determines whether or not an age-related increase in VWF levels is experienced, this may afford hematologists a way to predict which patients with type 1 VWD will experience an increase in VWF levels with age.

Effect of Age on Bleeding Symptoms in von Willebrand Disease

Whether or not an age-related increase in VWF levels results in reduced bleeding in VWD is uncertain. An estrogen-related increase in VWF levels during hormonal therapy or pregnancy improves bleeding symptoms, and increasing VWF levels with DDAVP prevents periprocedural bleeding; however, it is hypothesized greater than normal VWF levels may be necessary for adequate hemostasis with aging, so normalization of VWF levels may not necessarily result in reduced bleeding. This issue has been explored in a few studies (–Table 2).

The multicenter, prospective MCMDM-1 VWD study in Europe enrolled patients with an institutional diagnosis of type 1 VWD. There was no specific VWF level identified for inclusion in the study; however, the median VWF:Ag level and VWF:RCo activity were 0.33 and 0.34 IU/mL, respectively, in 144 index cases, and 0.36 and 0.35 IU/mL, respectively, in 273 affected family members. The median VWF:Ag level and VWF:RCo activity were normal in unaffected family members and controls. The study demonstrated a trend for increasing bleeding score with age in index cases and affected family members, but not unaffected family members or controls, using the expert-administered MCMDM-1 VWD BAT at the time of diagnosis. The study showed the existence of a strong inverse relationship between bleeding score and VWF levels, p < 0.001. In contrast, in the previously discussed Zimmerman Program, using the expert-administered International Society on Thrombosis and Haemostasis BAT, Flood et al found no correlation between VWF:Ag levels and bleeding score in patients with type 1 VWD, although 24% of patients had a normal bleeding score.

In the previously discussed WiN study, using the MCMDM-1 VWD BAT, Sanders et al found no difference in the median bleeding score between elderly VWD patients, 65 years of age and older, and younger VWD patients, less than 65 years of age, 12 versus11, p = 0.154, respectively. Nor was there any difference in the median bleeding score when the two groups were compared separately according to VWD subtype, type 1 VWD, p = 0.293, and type 2 VWD, p = 0.238. In addition, at the time of inclusion in the study, patients were asked to report bleeding symptoms experienced during the previous year that required VWD-specific treatment. There was no difference in reported bleeding symptoms between older and younger type 1 VWD patients, 23% versus 30%, p = 0.271. In contrast, older type 2 VWD patients reported more bleeding symptoms than young patients, 59% versus 39%, p = 0.046. Similar to the general population, gastrointestinal bleeding was more common in older patients. In the same cohort of patients, using the self-administered condensed MCMDM-1 VWD BAT, de Wee et al reported a 0.8 increase in bleeding score every 10 years of age. Again, from the WiN study, using the condensed MCMDM-1 VWD BAT, Atiq et al reported a total bleeding score of 1.9 (95% CI, 0.1–3.8) higher and more frequent bleeding events in the previous year, 29.2% versus 18.4%, p = 0.030, among type 1 VWD patients with comorbid...
illnesses. These differences were not seen in patients with type 2 VWD.

Based on the above studies, it appears bleeding symptoms are not lessened with age, and in fact, may worsen; however, certain study-specific limitations, which may affect the validity of these findings, require further discussion. First, none of the studies investigated as their first objective, the effect of age on bleeding symptoms in patients with type 1 VWD. Second, BAT administration may not have accurately reflected current bleeding risk due to the cumulative score effect. For example, a patient may have had a significant number of bleeding symptoms in early adulthood corresponding to a high bleeding score; however, even if bleeding manifestations lessen, or completely resolve with age, the bleeding score will remain unchanged. This may prevent a proper assessment of the patient’s current bleeding phenotype. Lastly, comorbidities, such as liver disease, kidney disease, malignancy, etc., occur with increased incidence in older adults and affect non-VWD-related bleeding risk; thus, they may serve as potential confounders. It is not surprising that patients with comorbid illnesses experienced more frequent bleeding, regardless of VWF:Ag level, in the Atiq et al study. To counter some of these limitations, our group performed a retrospective cohort study of 43 patients with an institutional diagnosis of type 1 VWD. No specific VWF level was identified for inclusion in the study. VWF levels and the condensed MCMDM-1 BAT were performed
during routine clinic visits. The bleeding score was determined as an interim BAT, based on bleeding symptoms present during the prior 3 years, rather than lifelong. There was no association between VWF levels and age; however, the mean VWF:Ag level was 0.83 ± 0.37 IU/mL, and the mean VWF:RCo activity was 0.59 ± 0.34 IU/mL. This may have been confounded by the fact that 34% of patients were receiving estrogen containing hormonal therapy. The bleeding score was found to be inversely associated with age. The bleeding score decreased 0.080, p < 0.01, per year of life. Comorbidities were not assessed.

Clinical Vignette Conclusion

Based on the patient’s recent lack of bleeding symptoms, current normal VWF levels, and cardiovascular risk factors, periprocedural VWD-specific therapy was omitted. The patient underwent an uncomplicated laparoscopic sigmoid colectomy. Postoperative pharmacologic venous thromboembolysis was not recommended. The patient experienced no bleeding or thrombotic events. The patient was recommended to have VWF levels checked prior to future invasive procedures to determine the need for VWD-specific therapy on a case-by-case decision.

Conclusion

Based on the current state of the literature, VWF levels increase with age in patients with “low VWF” and type 1 VWD, thus may be more likely to occur in patients without a pathogenic VWF mutation, and may be the consequence of comorbid illnesses. Whether normalization of VWF levels results in amelioration of bleeding symptoms is uncertain. In the case we present, it appears at least some patients as they age may tolerate invasive procedures without VWD-specific therapy. Whether with age, a new “supernormal” VWF level is necessary for hemostasis, and if so, what the value is, remains unclear. The current findings are conflicting, possibly due to study-specific differences, patient-specific characteristics, primary study objectives, method of BAT administration, and confounding due to comorbid illnesses.

Determining whether or not bleeding risk is reduced in aging type 1 VWD patients is essential to providing hematologists the knowledge needed to deliver appropriate medical care to affected patients. Aging patients commonly undergo invasive procedures. If older type 1 VWD patients have experienced normalization of VWF levels, and no longer have an increased risk of bleeding, administration of VWD-specific therapy may be harmful, especially among patients with underlying cardiovascular disease or related risk factors, and unnecessarily costly. For these reasons, further investigation into the effect of age on VWF levels and bleeding risk in VWD patients is sorely needed. Ideally, large, multicenter cross-sectional or prospective observational studies of type 1 VWD patients measuring current bleeding symptoms while accounting for non-VWD-related bleeding risks are desired, and our institution will be leading a multicenter, cross-sectional study to begin this task.

Authors’ Contributions

C.D.S. and M.V.R. researched the topic, analyzed the data, formulated the conclusions, and wrote the paper.

Funding

This study was funded by the University of Pittsburgh Cancer Institute.

Conflict of Interest

M.V.R. reports grants and other from Alnylam/Sanofi, Biomarin, Bioverativ and SPARK, and grants from Sангamo, during the conduct of the study. C.D.S. reports personal fees from Bayer, Takeda, Spark Therapeutics, Genentech, outside the submitted work.

References

1 Lillicrap D. von Willebrand disease: advances in pathogenetic understanding, diagnosis, and therapy. Blood 2013;122(23): 3735–3740
17 Atiq F, Meijer K, Eikenboom J, et al; WIN study group. Comorbidities associated with higher von Willebrand factor (VWF) levels
may explain the age-related increase of VWF in von Willebrand disease. Br J Haematol 2018;182(01):93–105